Sterile Preparations
Help Questions
NAPLEX › Sterile Preparations
A 6-year-old male (20 kg) with acute lymphoblastic leukemia is scheduled for vincristine 1.2 mg IV today (hazardous drug). Allergies: none. Labs: SCr 0.4 mg/dL, AST 20 units/L, ALT 16 units/L, WBC 2,100/mm$^3$, platelets 85,000/mm$^3$. Current medications: trimethoprim-sulfamethoxazole 80/400 mg by mouth twice daily on weekends, ondansetron 4 mg by mouth every 8 hours as needed. The dose will be compounded in a negative-pressure ISO Class 7 hazardous buffer room using an ISO Class 5 biological safety cabinet (BSC) and transported to the infusion center. Which personal protective equipment is required for this preparation?
One pair of sterile gloves and a hair cover only, because the PEC provides product and personnel protection
N95 respirator only, because vincristine is primarily a vapor hazard
One pair of sterile chemotherapy gloves and a surgical mask; gown optional if working in a BSC
Two pairs of chemotherapy gloves and a chemotherapy gown; add eye/face protection if splash risk exists
Explanation
The concept being tested is personal protective equipment (PPE) requirements for handling hazardous drugs under USP <800>. The key factor is the hazardous nature of vincristine, requiring enhanced protection during compounding in a biological safety cabinet (BSC) for the pediatric leukemia patient. Choice B is the best because two pairs of chemotherapy gloves and a chemotherapy gown provide barrier protection against exposure, with eye/face protection added for splash risks, ensuring personnel and patient safety. Choice A is incorrect as one pair of gloves and optional gown underestimate hazardous drug risks, even in a BSC, leading to potential contamination. Choices C and D are suboptimal because minimal gloves/hair cover ignore full PPE needs, and N95 is for airborne hazards not primary for vincristine, common errors in hazardous compounding. A transferable pearl is to always use USP <800>-compliant PPE for hazardous drugs, including double gloving and dedicated gowns. Proper aseptic technique involves maintaining negative pressure in hazardous buffer rooms to contain contaminants.
A 76-year-old male (74 kg) with sepsis is ordered norepinephrine 8 mg in 250 mL D5W as a continuous IV infusion. Allergies: none. Labs: SCr 1.8 mg/dL, AST 40 units/L, ALT 33 units/L, WBC 19,000/mm$^3$. Current medications: vasopressin infusion, meropenem 1 g IV every 8 hours. The pharmacy will batch compound multiple norepinephrine bags for the ICU using an ISO Class 5 PEC in an ISO Class 7 buffer room, and store them refrigerated until needed. What is the appropriate beyond-use date for this compound?
7 days refrigerated because it is compounded in an ISO Class 7 buffer room
24 hours refrigerated because it is a low-risk CSP
28 days refrigerated because norepinephrine is chemically stable
48 hours refrigerated because it is a low-risk CSP
Explanation
The concept being tested is beyond-use date (BUD) assignment for batched low-risk compounded sterile preparations (CSPs) stored refrigerated. The key factor is the batch compounding of norepinephrine infusions in an ISO Class 5 PEC for ICU use in a septic patient. Choice B is the best because 48 hours refrigerated fits low-risk CSP guidelines for batched items, balancing stability and safety. Choice A is incorrect as 24 hours underestimates allowable time, potentially increasing workload. Choices C and D are suboptimal because 7 or 28 days exceed low-risk limits without testing, risking degradation. A transferable pearl is to protect light-sensitive drugs like norepinephrine during storage. Proper aseptic technique includes using friction when disinfecting with 70% isopropyl alcohol.
A 3-day-old premature neonate (1.2 kg) in the neonatal intensive care unit requires a customized total parenteral nutrition (TPN) bag. Allergies: none. Labs: SCr 0.6 mg/dL, AST 35 units/L, ALT 18 units/L, total bilirubin 6.2 mg/dL, WBC 9,500/mm$^3$, potassium 3.4 mEq/L, magnesium 1.6 mg/dL, phosphate 3.0 mg/dL. Current medications: ampicillin 50 mg/kg IV every 12 hours, gentamicin 4 mg/kg IV every 24 hours. The TPN will be compounded in an ISO Class 5 PEC within an ISO Class 7 buffer room and includes calcium gluconate and sodium phosphate additives. What is the most critical step in preparing this sterile product?
Use 0.9% sodium chloride as the primary diluent to reduce precipitation of calcium phosphate
Verify calcium and phosphate compatibility and add them in an order that reduces precipitation risk (typically phosphate first, calcium later)
Add calcium gluconate and sodium phosphate early and simultaneously to minimize compounding time
Filter the final TPN through a 5-micron filter to remove precipitates before dispensing
Explanation
The concept being tested is preventing incompatibility in total parenteral nutrition (TPN) compounding. The key factor is the risk of calcium phosphate precipitation in the customized TPN for a premature neonate with specific electrolyte needs. Choice B is the best because verifying compatibility and adding phosphate first then calcium minimizes precipitation, ensuring solution stability and patient safety. Choice A is incorrect as adding them simultaneously increases precipitation risk, a common error in hurried compounding. Choices C and D are suboptimal because sodium chloride may not prevent issues, and filtering does not address root causes, potentially clogging lines. A transferable pearl is to use compatibility charts and sequential addition for electrolytes in TPN. Proper PPE includes sterile gloves and gowns in the buffer room to maintain asepsis.
A 45-year-old male (95 kg) with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is ordered daptomycin 600 mg IV now. Allergies: none. Labs: SCr 1.3 mg/dL, creatine kinase 110 units/L, AST 24 units/L, ALT 19 units/L, WBC 14,200/mm$^3$. Current medications: atorvastatin 40 mg by mouth nightly, normal saline at 100 mL/hour. The dose is compounded from a single-dose vial, diluted in 50 mL of 0.9% sodium chloride, and will be stored at room temperature on the unit for administration during rounds. What is the appropriate beyond-use date for this compound?
1 hour at room temperature because it is an urgent dose
14 days refrigerated because it was prepared from a sterile vial
24 hours at controlled room temperature because it is a low-risk CSP
12 hours at controlled room temperature because it is a low-risk CSP
Explanation
The concept being tested is assigning beyond-use dates (BUDs) for low-risk compounded sterile preparations (CSPs) stored at room temperature. The key factor is the room temperature storage of the daptomycin infusion prepared from a single-dose vial for a patient with MRSA bacteremia. Choice B is the best because 12 hours at controlled room temperature matches low-risk CSP guidelines, preventing microbial growth and ensuring safety for prompt administration. Choice A is incorrect as 1 hour is for immediate-use only, not applicable here, leading to unnecessary waste. Choices C and D are suboptimal because 24 hours or 14 days exceed low-risk limits for room temperature, risking contamination, common errors in BUD miscalculation. A transferable pearl is to consider drug-specific stability alongside USP <797> risk levels when assigning BUDs. Proper aseptic technique requires avoiding contact with critical sites and using sterile 70% isopropyl alcohol for disinfection.
A 72-year-old female (60 kg) with atrial fibrillation and inability to take oral medications is ordered amiodarone 150 mg IV in 100 mL of 5% dextrose (D5W) to infuse over 10 minutes. Allergies: none. Labs: SCr 1.0 mg/dL, AST 44 units/L, ALT 51 units/L, WBC 7,800/mm$^3$. Current medications: heparin infusion per protocol, metoprolol 5 mg IV as needed. The pharmacy will compound the infusion in an ISO Class 5 PEC in an ISO Class 7 buffer room and send it immediately to the ICU. Which environmental condition is crucial for this preparation?
A laminar airflow workbench may be placed in a nonclassified area if the surface is disinfected between doses
A positive-pressure hazardous buffer room is required for all IV admixtures to prevent contamination
An ISO Class 5 PEC with HEPA-filtered unidirectional airflow must be used for critical sites and components
Compounding must occur in an ISO Class 8 room as long as the product is used within 1 hour
Explanation
The concept being tested is environmental controls required for sterile compounding under USP <797>. The key factor is the need for ISO-classified airflow to protect critical sites during preparation of amiodarone infusion for a patient unable to take oral medications. Choice B is the best because an ISO Class 5 PEC with HEPA-filtered unidirectional airflow safeguards components from contamination, ensuring sterile integrity and patient safety in the ICU. Choice A is incorrect as ISO Class 8 alone does not provide adequate protection, even for short use, risking microbial introduction. Choices C and D are suboptimal because positive-pressure hazardous rooms are for containment not non-hazardous drugs, and nonclassified areas violate standards, common errors in environmental setup. A transferable pearl is to certify PECs every 6 months for airflow and particle counts. Proper PPE guidelines include shoe covers, hair covers, and sterile gloves in the buffer room.
A 65-year-old female (59 kg) is receiving ganciclovir 5 mg/kg IV every 12 hours for cytomegalovirus infection (hazardous drug per many institutional policies). Allergies: none. Labs: SCr 1.6 mg/dL, AST 28 units/L, ALT 26 units/L, WBC 2,400/mm$^3$. Current medications: tacrolimus, mycophenolate, prednisone. The pharmacy compounds ganciclovir doses in an ISO Class 5 PEC located in a negative-pressure hazardous buffer room and uses hazardous drug labeling for transport. Which personal protective equipment is required for this preparation?
No gloves are required if compounding occurs in an ISO Class 5 PEC
Surgical mask and hair cover only, because dermal exposure is not a concern
Two pairs of chemotherapy gloves and a chemotherapy gown; add eye/face protection if splash risk exists
One pair of sterile gloves only, because ganciclovir is not an antineoplastic
Explanation
The sterile preparation concept being tested is the personal protective equipment (PPE) required for compounding non-antineoplastic hazardous drugs like ganciclovir in a hazardous drug setting. The key preparation-specific factor is that ganciclovir is classified as hazardous due to reproductive risks per NIOSH and institutional policies, necessitating handling in a negative-pressure hazardous buffer room. Choice B is the best choice for ensuring sterile integrity and patient safety because it requires two pairs of chemotherapy gloves and a chemotherapy gown to prevent dermal exposure to hazardous residues, with added eye/face protection for splash risks, aligning with USP <800> for HDs. Choice A is incorrect because, despite not being antineoplastic, ganciclovir's hazardous status demands full PPE, not just sterile gloves, to avoid exposure errors; choice C is suboptimal as gloves are mandatory for all aseptic HD compounding to maintain barriers, even in an ISO Class 5 PEC; choice D is wrong because it ignores glove and gown needs, focusing on less critical areas while dermal contact remains a primary concern. A transferable sterile compounding pearl is to review the NIOSH hazardous drug list and perform risk assessments for each agent to tailor PPE appropriately. Frameworks like USP <800> emphasize combining PPE with engineering controls, such as PECs in buffer rooms, and proper technique to safeguard personnel and preparations.
A 29-year-old female (62 kg) with Crohn disease is ordered ustekinumab 390 mg IV induction dose. Allergies: none. Labs: SCr 0.7 mg/dL, AST 18 units/L, ALT 16 units/L, WBC 6,700/mm$^3$. Current medications: prednisone 20 mg by mouth daily, pantoprazole 40 mg by mouth daily. The biologic will be prepared as an IV infusion in an ISO Class 5 PEC within an ISO Class 7 buffer room and administered later the same day. Which environmental condition is crucial for this preparation?
A segregated compounding area without ISO classification is acceptable if the vial is preservative-free
A negative-pressure room is required for all monoclonal antibodies because they are hazardous
An ISO Class 9 room is acceptable if the infusion is administered within 2 hours
An ISO Class 5 PEC is required to provide unidirectional HEPA-filtered airflow over critical sites during compounding
Explanation
The concept being tested is environmental requirements for biologic sterile preparations. The key factor is the need for controlled airflow during ustekinumab infusion preparation for the Crohn disease patient. Choice A is the best because an ISO Class 5 PEC provides essential HEPA-filtered air over critical sites, ensuring sterility and safety. Choice B is incorrect as ISO Class 9 lacks sufficient control, even for short use, risking particulates. Choices C and D are suboptimal because negative pressure is for hazardous drugs, and segregated areas limit BUDs unnecessarily. A transferable pearl is to monitor pressure differentials daily in cleanroom suites. Proper aseptic technique avoids rapid movements that disrupt airflow.
A 52-year-old male (100 kg) with diabetic ketoacidosis is ordered an insulin infusion prepared as regular insulin 100 units in 100 mL of 0.9% sodium chloride. Allergies: none. Labs: SCr 1.0 mg/dL, potassium 5.6 mEq/L, bicarbonate 12 mEq/L, WBC 12,300/mm$^3$. Current medications: potassium replacement per protocol, normal saline boluses. The infusion is compounded in an ISO Class 5 PEC in an ISO Class 7 buffer room and will be hung immediately. Which technique ensures sterility in this preparation?
Remove needle caps by touching the needle hub to stabilize the cap during removal
Use a sterile alcohol pad to disinfect the bag’s injection port and allow it to dry before injecting insulin
Use tap water to rinse gloves if they become sticky during compounding
Disinfect the injection port after injecting insulin to prevent backflow contamination
Explanation
The concept being tested is aseptic techniques for insulin infusion compounding. The key factor is disinfecting the IV bag port before injecting insulin for the diabetic ketoacidosis patient. Choice A is the best because using sterile alcohol and allowing drying kills microbes, preventing contamination and ensuring infusion safety. Choice B is incorrect as post-injection disinfection does not prevent initial entry of contaminants. Choices C and D are suboptimal because tap water or touching hubs breaches sterility, common technique errors. A transferable pearl is to use luer-lock connections to secure infusions. Proper PPE guidelines prohibit jewelry in compounding areas to reduce bioburden.
A 41-year-old male (76 kg) with bacterial meningitis is ordered ceftriaxone 2 g IV every 12 hours; the next dose is needed in 30 minutes. Allergies: none. Labs: SCr 0.8 mg/dL, AST 20 units/L, ALT 22 units/L, WBC 18,600/mm$^3$. Current medications: dexamethasone 10 mg IV every 6 hours, acetaminophen 650 mg by mouth as needed. The pharmacy plans to compound a ceftriaxone minibag in a segregated compounding area (SCA) using an ISO Class 5 PEC because the buffer room is temporarily unavailable; the dose will be administered immediately after preparation. Which environmental condition is crucial for this preparation?
Compounding in an SCA is prohibited under all circumstances; the dose must be prepared on the nursing unit
Compounding in an SCA is acceptable if an ISO Class 5 PEC is used and the CSP is assigned a shorter beyond-use date per USP <797>
A positive-pressure ISO Class 7 buffer room is required even for immediate administration
An ISO Class 8 anteroom alone is sufficient if the PEC is disinfected before use
Explanation
The concept being tested is use of segregated compounding areas (SCAs) for urgent sterile preparations. The key factor is the temporary unavailability of the buffer room, necessitating SCA use for immediate ceftriaxone administration in meningitis. Choice A is the best because SCA with ISO Class 5 PEC allows compounding with shortened BUD per USP <797>, ensuring timely therapy and safety. Choice B is incorrect as SCA is permitted for Category 1 CSPs, not prohibited. Choices C and D are suboptimal because requiring buffer rooms or anterooms ignores SCA provisions, delaying care. A transferable pearl is to assign 12-hour RT BUD for Category 1 CSPs in SCAs. Proper framework includes daily cleaning of PECs in SCAs.
A 34-year-old female (64 kg) is ordered methotrexate 25 mg intrathecal (hazardous drug) for leukemia. Allergies: none. Labs: SCr 0.6 mg/dL, AST 22 units/L, ALT 18 units/L, WBC 1,900/mm$^3$. Current medications: leucovorin per protocol, acyclovir prophylaxis. The dose will be prepared in an ISO Class 5 BSC in a negative-pressure ISO Class 7 hazardous buffer room and dispensed in a syringe with a needleless cap. Which personal protective equipment is required for this preparation?
One pair of sterile gloves and a sterile gown only, because the product is administered intrathecally
Surgical mask only, because the BSC provides adequate protection from hazardous drugs
One pair of chemotherapy gloves and no gown to reduce shedding in the PEC
Two pairs of chemotherapy gloves, chemotherapy gown, and head/hair cover; add eye/face protection if splash risk exists
Explanation
The concept being tested is PPE requirements for hazardous intrathecal preparations under USP <800>. The key factor is the hazardous status of methotrexate, necessitating full protection for intrathecal compounding in a BSC. Choice A is the best because two pairs of chemotherapy gloves, gown, and head cover prevent exposure, with eye protection for splashes, ensuring safety for the leukemia patient. Choice B is incorrect as non-chemotherapy PPE underprotects against hazardous residues. Choices C and D are suboptimal because mask alone or single gloves ignore comprehensive needs, common PPE errors. A transferable pearl is to doff outer gloves before exiting the buffer room. Proper framework includes annual competency assessments for hazardous compounding.